AT Bancorp’s Clovis Oncology, Inc. CLVS Stock Holding History

AT Bancorp’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-15,309	Closed	-$450K	–	234
2018 Q3	$450K	Buy	15,309 +6,852	+81%	+$265K	0.05%	166
2018 Q2	$385K	Buy	+8,457	New	+$411K	0.04%	179

Other funds holding CLVS

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

AT Bancorp's CLVS Position: Q4 2018 in Review

AT Bancorp sold out of Clovis Oncology, Inc. (CLVS) in Q4 2018, closing a stake of 15,309 shares — an estimated $450K sold.

AT Bancorp first reported a position in CLVS in Q2 2018 and held it in 2 quarters. The position peaked at $450K in Q3 2018. 165 funds tracked by Wall St. Rank hold CLVS as of Q4 2018.

AT Bancorp reported no remaining Clovis Oncology, Inc. position as of Q4 2018 after selling out during the quarter.
AT Bancorp sold 15,309 Clovis Oncology, Inc. shares in Q4 2018, an estimated $450K.
AT Bancorp first reported a position in Clovis Oncology, Inc. in Q2 2018 and held it in 2 quarters.
AT Bancorp's Clovis Oncology, Inc. position peaked at $450K in Q3 2018.
165 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2018.

Based on AT Bancorp's 13F filing for Q4 2018, filed 14 Feb 2019.